Navigation Links
Sangamo BioSciences Announces Presentation at the 2014 Morgan Stanley Global Healthcare Conference
Date:9/3/2014

RICHMOND, Calif., Sept. 3, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:10 am ET on Wednesday, September 10, 2014, at the 2014 Morgan Stanley Global Healthcare Conference. The conference is being held in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures™ for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases.  The company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation At The 2014 Wedbush Securities Life Sciences Management Access Conference
2. Sangamo BioSciences Reports Second Quarter 2014 Financial Results
3. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
4. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
5. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
6. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
7. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
8. Sangamo BioSciences Reports Third Quarter 2013 Financial Results
9. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
10. Sangamo BioSciences Proposes Public Offering Of Common Stock
11. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Alto, CA, USA (PRWEB) , ... March 29, 2017 , ... ... in various regulatory subjects has announced its 3rd Annual Medical Device Summit 2017 venue ... at the Omni Parker House Hotel, in Boston, MA. , The Omni Parker House ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... cell-based assays, disperses a quarterly travel award to noteworthy scientists who will be ... announced that its new round of awards are being given to two postdoctoral ...
(Date:3/29/2017)... NEWARK, Del. , March 29, 2017 ... and W. L. Gore & Associates, Inc. ... collaborative research agreement whereby the two companies will work ... technologies that provide protection from immune rejection. ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:3/29/2017)... , March 29, 2017 The Global Microfluidic ... report is a specialized and comprehensive study on the existing state ... America , Europe and ... Middle East and Africa . ... Browse 172 Tables and ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):